These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10461819)

  • 1. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.
    Szigethy E; Wiznitzer M; Branicky LA; Maxwell K; Findling RL
    J Child Adolesc Psychopharmacol; 1999; 9(2):93-8. PubMed ID: 10461819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone and liver function tests in children and adolescents: a short-term prospective study.
    Erdogan A; Atasoy N; Akkurt H; Ozturk D; Karaahmet E; Yalug I; Yalug K; Ankarali H; Balcioglu I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):849-57. PubMed ID: 18258348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey.
    Erdogan A; Karaman MG; Ozdemir E; Yurteri N; Tufan AE; Kurcer MA
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):407-13. PubMed ID: 20973711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study.
    Atasoy N; Erdogan A; Yalug I; Ozturk U; Konuk N; Atik L; Ustundag Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1255-60. PubMed ID: 17600607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
    Martin A; Landau J; Leebens P; Ulizio K; Cicchetti D; Scahill L; Leckman JF
    J Child Adolesc Psychopharmacol; 2000; 10(4):259-68. PubMed ID: 11191686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone-associated steatohepatitis and excessive weight-gain.
    Holtmann M; Kopf D; Mayer M; Bechtinger E; Schmidt MH
    Pharmacopsychiatry; 2003 Sep; 36(5):206-7. PubMed ID: 14571356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver function tests in children and adolescents receiving risperidone treatment for a year: a longitudinal, observational study from Turkey.
    Karaman MG; Erdoğan A; Tufan E; Yurteri N; Ozdemir E; Ankarali H
    Int J Psychiatry Clin Pract; 2011 Sep; 15(3):204-8. PubMed ID: 22121930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.
    Kelly DL; Conley RR; Love RC; Horn DS; Ushchak CM
    J Child Adolesc Psychopharmacol; 1998; 8(3):151-9. PubMed ID: 9853689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone- and quetiapine-induced cholestasis.
    Wright TM; Vandenberg AM
    Ann Pharmacother; 2007 Sep; 41(9):1518-23. PubMed ID: 17666578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity.
    López-Torres E; Süveges A; Peñas-LLedó EM; Doña A; Dorado P; LLerena A; Berecz R
    Drug Metabol Drug Interact; 2014; 29(2):123-6. PubMed ID: 24598833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study.
    Rettenbacher MA; Baumgartner S; Eder-Ischia U; Edlinger M; Graziadei I; Hofer A; Huber R; Hummer M; Kemmler G; Weiss E; Fleischhacker WW
    J Clin Psychopharmacol; 2006 Oct; 26(5):500-3. PubMed ID: 16974192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
    Martin A; Scahill L; Anderson GM; Aman M; Arnold LE; McCracken J; McDougle CJ; Tierney E; Chuang S; Vitiello B
    Am J Psychiatry; 2004 Jun; 161(6):1125-7. PubMed ID: 15169706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study: risperidone-induced hepatotoxicity in pediatric patients.
    Kumra S; Herion D; Jacobsen LK; Briguglia C; Grothe D
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):701-5. PubMed ID: 9136506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
    Hellings JA; Zarcone JR; Crandall K; Wallace D; Schroeder SR
    J Child Adolesc Psychopharmacol; 2001; 11(3):229-38. PubMed ID: 11642473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
    Malone RP; Maislin G; Choudhury MS; Gifford C; Delaney MA
    J Am Acad Child Adolesc Psychiatry; 2002 Feb; 41(2):140-7. PubMed ID: 11837403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
    Zuddas A; Di Martino A; Muglia P; Cianchetti C
    J Child Adolesc Psychopharmacol; 2000; 10(2):79-90. PubMed ID: 10933118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case study: risperidone treatment of children and adolescents with developmental disorders.
    Hardan A; Johnson K; Johnson C; Hrecznyj B
    J Am Acad Child Adolesc Psychiatry; 1996 Nov; 35(11):1551-6. PubMed ID: 8936923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.